Meroglan

# Meroglan ## Overview - **Classification**: Novel Carbapenem Derivative (Broad-spectrum Beta-lactam Antibiotic) - **Mechanism**: Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to bacterial cell lysis and death. Possesses enhanced stability against various beta-lactamases. ## Primary Indications 1. **Complicated Intra-abdominal Infections (cIAI)** - Including polymicrobial infections. 2. **Complicated Urinary Tract Infections (cUTI)** - Including pyelonephritis and infections with bacteremia. 3. **Hospital-Acquired Pneumonia (HAP) / Ventilator-Associated Pneumonia (VAP)** - Treatment of severe respiratory tract infections. 4. **Bacterial Meningitis** - For susceptible strains, due to good CNS penetration. ## Adult Dosing ### Standard Dosing **Complicated Intra-abdominal Infections (cIAI) / Complicated Urinary Tract Infections (cUTI)** - **Dose**: **1 gram** - **Frequency**: Every **8 hours** - **Route**: Intravenous (IV) infusion over **30-60 minutes** - **Duration**: 5-14 days, guided by clinical response **Hospital-Acquired Pneumonia (HAP) / Ventilator-Associated Pneumonia (VAP)** - **Dose**: **1 gram** - **Frequency**: Every **8 hours** - **Route**: Intravenous (IV) infusion over **30-60 minutes** - **Duration**: 7-14 days **Bacterial Meningitis** - **Dose**: **2 grams** - **Frequency**: Every **8 hours** - **Route**: Intravenous (IV) infusion over **30-60 minutes** - **Duration**: 7-21 days, based on pathogen and response ### Dose Adjustments - **Renal Impairment**: Requires significant adjustment. - CrCl **>50 mL/min**: No adjustment. - CrCl **26-50 mL/min**: **1 gram** IV every **12 hours**. - CrCl **10-25 mL/min**: **500 mg** IV every **12 hours**. - CrCl **<10 mL/min**: **500 mg** IV every **24 hours**. - **Hemodialysis (HD)**: Administer **500 mg** IV after each HD session. - **Hepatic Impairment**: No dose adjustment generally required. - **Elderly Patients**: Adjust dose based on renal function (CrCl) rather than age alone. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: **20 mg/kg/dose** - **Frequency**: Every **12 hours** - **Maximum**: **1 gram** per dose - **Special Notes**: Infuse IV over **30-60 minutes**. Monitor for CNS effects. ### Infants (1-12 months) - **Dose**: **30 mg/kg/dose** - **Frequency**: Every **8 hours** - **Maximum**: **1 gram** per dose - **Special Notes**: For serious infections, up to **40 mg/kg/dose** may be considered. ### Children (1-12 years) - **Dose**: **40 mg/kg/dose** - **Frequency**: Every **8 hours** - **Maximum**: **2 grams** per dose (up to **6 grams** per day) - **Special Notes**: For meningitis, consider **40-66 mg/kg/dose** every 8 hours, max 2g/dose. ### Adolescents (13-18 years) - **Dose**: Administer adult dosing recommendations. - **Maximum**: **2 grams** per dose (up to **6 grams** per day) - **Special Notes**: Renal adjustments apply as per adult guidelines. ## Safety Information ### Contraindications - **Absolute**: Known hypersensitivity to Meroglan or other carbapenem antibiotics. - **Absolute**: History of severe hypersensitivity (e.g., anaphylaxis, Stevens-Johnson syndrome) to any beta-lactam antibiotic. ### Common Adverse Effects - **Very Common (>10%)**: Diarrhea, Nausea/Vomiting, Headache - **Common (1-10%)**: Rash, Injection site reactions, Seizures (especially with high doses/renal dysfunction), Hypokalemia - **Serious but Rare**: Anaphylaxis, *Clostridioides difficile*-associated diarrhea (CDAD), Hemolytic anemia, Encephalopathy ### Key Drug Interactions - **Valproic Acid/Divalproex**: Meroglan significantly decreases valproic acid levels, leading to loss of seizure control. - **Clinical Significance**: Co-administration is generally **contraindicated**. Consider alternative antibiotics or anticonvulsants. - **Probenecid**: Inhibits renal tubular secretion of Meroglan, increasing its plasma concentration and half-life. - **Clinical Significance**: Not recommended; may increase toxicity. - **Oral Anticoagulants (e.g., Warfarin)**: May enhance anticoagulant effect. - **Monitoring Requirement**: Monitor INR closely. ## Monitoring & Follow-up - **Before Treatment**: Obtain culture and sensitivity, assess renal function (CrCl), baseline CBC, LFTs. - **During Treatment**: - Monitor renal function (SCr, BUN) at least every **2-3 days** (more frequently in renal impairment). - Monitor LFTs and CBC weekly. - Observe for signs of seizures, especially in patients with pre-existing CNS disorders or renal impairment. - Monitor for signs of superinfection or CDAD. - **Clinical Signs**: Watch for fever resolution, improvement in infection symptoms, or signs of adverse reactions (e.g., rash, altered mental status). ## Clinical Pearls - 💡 **Seizure Risk**: Meroglan, like other carbapenems, can lower the seizure threshold. Administer slowly and adjust dose in renal impairment to minimize risk. - 💡 **Infusion Time**: Always infuse IV over **30-60 minutes**; rapid infusion increases seizure risk and infusion site reactions. - 💡 **Spectrum**: Provides broad-spectrum coverage, including many Gram-positive, Gram-negative, and anaerobic bacteria. Reserve for serious infections to prevent resistance. - 💡 **Valproic Acid**: Strongly advise against co-administration with valproic acid due to precipitous drop in anticonvulsant levels. - 💡 **Storage**: Reconstituted solutions should be used promptly. Follow manufacturer guidelines for stability. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.